Navigation Links
Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Date:10/26/2008

Data Analysis of Up to Four Years of Treatment Presented at ICAAC/IDSA 2008 Annual Meeting

WASHINGTON, Oct. 26 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported a data analysis showing that vicriviroc, its investigational CCR5 receptor antagonist, demonstrated sustained viral suppression and increased CD4 cell counts and was well tolerated through up to four years of therapy in treatment-experienced HIV-infected patients. Vicriviroc was administered once-daily as a single tablet in combination with an optimized antiretroviral regimen containing a ritonavir-boosted protease inhibitor. These results represent the longest treatment duration and clinical experience reported to date for a CCR5 receptor antagonist.

Vicriviroc, currently in Phase III development, is an extracellular inhibitor of HIV infection designed to prevent the virus from infecting the immune system's CD4 cells by blocking the CCR5 co-receptor. Approximately 50-60 percent of treatment-experienced patients have virus that uses the CCR5 co-receptor.(1)

Researchers presented the data at the joint Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Diseases Society of America (IDSA) annual meeting.(2)

The pooled data analysis involved 205 treatment-experienced HIV-infected patients from two vicriviroc Phase II studies who continued on vicriviroc at the completion of 48 weeks of treatment in an open-label extension for each study. Patients received vicriviroc for up to 216 weeks of total treatment duration as part of an optimized antiretroviral regimen.

This analysis showed that vicriviroc was well tolerated overall, with patients developing few complications of HIV disease. Adve
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Pa. , Sept. 1, 2015 ... fully integrated specialty pharmaceutical company focused on discovering, ... that researchers will be  presenting scientific data on ... an abuse-deterrent, extended-release, oral morphine product candidate, and ... development, at PainWeek 2015 to be ...
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, ... of the cardiovascular image management market, Frost ... with the 2015 European Frost & Sullivan ... Netherlands -based PMI has designed innovative ... product lines—which deliver precise and reproducible quantitative ...
(Date:9/1/2015)... , September 1, 2015 BerGenBio ... today announces that it has appointed Hilde Furberg ... Directors to its Board of Directors, effective immediately. ... of experience in pharma and biotech and is currently ... Sanofi company. Previously her role was Vice President and ...
Breaking Medicine Technology:Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 3Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 4Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 5Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 6Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 2Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 3Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 4Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 5BerGenBio Appoints Non-Executive Directors 2
... Oct. 25 The National Community Pharmacists Association (NCPA) ... Digest, sponsored by Cardinal Health , which found that ... their business in 2009 despite a stagnant economy, the ... drug reimbursements and the questionable business practices of pharmacy ...
... Panasonic Corporation of North America has completed an investment ... Medical Technologies which works closely with the Texas Medical ... establish itself as a global leader in Personalized Preventive ... to establish a presence in the world,s largest medical ...
Cached Medicine Technology:NCPA Digest Finds Independent Community Pharmacies Stable Despite Economic, Third-Party Challenges 2NCPA Digest Finds Independent Community Pharmacies Stable Despite Economic, Third-Party Challenges 3NCPA Digest Finds Independent Community Pharmacies Stable Despite Economic, Third-Party Challenges 4Panasonic Makes Investment in Houston-based CardioNexus Corp. 2Panasonic Makes Investment in Houston-based CardioNexus Corp. 3Panasonic Makes Investment in Houston-based CardioNexus Corp. 4
(Date:9/1/2015)... ... 01, 2015 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... awareness initiative, the nation’s premier and most high-profile lymphoma awareness campaign. Since its ...
(Date:9/1/2015)... ... September 01, 2015 , ... From Aug. 17-21, Calvary Hospital hosted the 18th ... Calvary’s Camp Compass® has taken place at Kingsborough Community College in Brooklyn in each ... whom work for Calvary, and two junior counselors who were campers themselves just a ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... aid colleges and universities across the country in stemming sexual assaults on their ... Climate Collaborative (ARC3), a consortium of sexual assault researchers and student affairs professionals ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... options, Blue Cross and Blue Shield of Minnesota (Blue Cross) has announced Doctor ... , Based in San Francisco, Doctor On Demand provides immediate access to Board ...
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia ... Machine,” is still strongly maintaining her firm’s success in the hair care and ... her upcoming city-to-city tour, Ellis will be providing “Look and learn” live demonstrations, ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2
... companies to different moral standards than other organizations, according ... Consumer Research . "Imagine the CEO of ... the business of maximizing shareholder profitability and fully intends ... prices should be very high because of limited competition," ...
... bed has to deal with numerous complications. Frequently, they ... them. Bony prominences, such as the sacrum, coccyx and ... to tissue necrosis. Damage can extend into the periosteum ... are entryways for germs, which can trigger sepsis. While ...
... the US Prostate Cancer Prevention Trial found cancer in many ... debated which PSA level should lead to a biopsy recommendation. ... amid considerable controversy, that the evidence does not support recommending ... because the risks outweigh the benefits. Now, a study ...
... MONDAY, Dec. 12 (HealthDay News) -- Acupuncture may help ... to a new study. Cancer drugs called taxanes, ... especially in the calves and feet, resulting in severe ... no effective treatment for the condition, called chemotherapy induced ...
... By Steven Reinberg HealthDay Reporter , MONDAY, ... drugs for attention deficit-hyperactivity disorder (ADHD) do not seem to ... finds. There have been fears that these drugs can ... large, observational study found no evidence that these effects posed ...
... -- A 59-year-old woman from upstate New York and ... were the first patients in New York state and ... transplanted lungs that were assessed and reconditioned in the ... to dramatically increase the availability of lungs for transplant. ...
Cached Medicine News:Health News:Commercial or communal: Why is outsourcing taboo for churches and pharmaceutical companies? 2Health News:Lying and sitting more comfortably 2Health News:Biopsy referral after PSA screening stays consistent over time 2Health News:Acupuncture Might Ease Chemotherapy Pain 2Health News:ADHD Drugs Don't Raise Risk of Heart Problems: Study 2Health News:ADHD Drugs Don't Raise Risk of Heart Problems: Study 3Health News:NewYork-Presbyterian/Columbia surgeons perform first 'ex vivo' lung transplants in New York 2
Designed to determine the precise length of limbal incisions and proper alignment of closing sutures. Curved marking blade with 2 mm lines spaced 1 mm apart-measures up to 10 mm. Round knurled handle...
Measures up to 152 mm in 1 mm increments and 6 inches in 1/32 inch increments. Deeply etched graduations and dull finish....
Rigid Endoscopes....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: